

### A multipurpose 'CZL' vaginal ring for non-hormonal contraception and STI/HIV prevention

Zhao, X., Boyd, P., Dallal Bashi, Y., McCoy, C. F., Shen, X., Lamb, D., Kumar, N., Singer, P., Mitchell, L., & Malcolm, K. (2023). *A multipurpose 'CZL' vaginal ring for non-hormonal contraception and STI/HIV prevention*. Poster session presented at 2023 National Contraception Meeting, Houston, United States.

### **Document Version:**

Publisher's PDF, also known as Version of record

### Queen's University Belfast - Research Portal: Link to publication record in Queen's University Belfast Research Portal

Publisher rights

Copyright 2023 the Authors.

#### General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

### Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.

### **Open Access**

This research has been made openly available by Queen's academics and its Open Research team. We would love to hear how access to this research benefits you. – Share your feedback with us: http://go.qub.ac.uk/oa-feedback

# A Multipurpose 'CZL' Vaginal Ring for Non-hormonal Contraception and **STI/HIV Prevention**



**QUEEN'S** BELFAST

## Background

Marketed contraceptive vaginal rings (VR) rely upon sustained/controlled release of either a progestin (e.g., Progering<sup>®</sup>) or a progestin/estrogen combination (e.g., NuvaRing<sup>®</sup>, Annovera<sup>®</sup>). Here we report formulation development and testing of a new non-hormonal multipurpose VR incorporating three actives – copper sulphate anhydrous (CSA), zinc lactate anhydrous (ZLA), and lactide (L; hydrolyses to lactic acid, LA) (aka. 'CZL' ring) – and offering spermicidal, antibacterial and antiviral activity.

## Key points

- All VR formulations 30% w/w CSA (30CSA), 30% w/w L (**30L**), 10% w/w CSA + 20% w/w L (**10CSA-20L**), 10% w/w CSA + 10% w/w ZLA + 10% w/w L (**10CSA-10ZLA-10L**), and 10% w/w CSA + 10% w/w ZLA + 20% w/w L (**10CSA-10ZLA-20L**) were successfully manufactured.
- The dimension of five VR formulations is ~57.4 x ~7.3 mm, and the weight varied with type within 7.8–9.3 g.
- The actives were not impacted by the VR manufacturing process, as evidenced by DSC and TGA data.
- Mechanical properties similar to marketed VR products (20 mm compression force, Shore M hardness values and percentage of elongation at break ranged 0.8–4.3 N, 41– 67, 248%–564% respectively).
- Sustained and continuous release of copper and zinc ions (2–31 and 1–17 mg/day) and lactide/lactic acid (12–105 mg/day) was observed for all VRs over 30 days; these values are considered in the ballpark for clinical efficacy based on *in vitro* sperm motility/antibacterial/antiviral data (see other poster).
- VRs containing lactide maintained pH of the release medium within the range 2.2–4.6, consistent with (i) release of lactide and rapid hydrolysis to lactic acid and (ii) the pH modulating effects associated with CSA and ZLA.
- The data support the continued development of the multipurpose CZL VR concept.

## Acknowledgements

The work was supported by NIH grant 5P50HD106793-02 ('Contraception development research center to advance a novel intravaginal ring as a non-hormonal multipurpose prevention technology').

following IVRT (**dried**).



Figure 4. Daily release of zinc ions (A), cumulative release of zinc ions (C) cumulative release of copper ions (D), daily release of lactic acid (E) and cumulative release of lactic acid (**F**) into deionized water (60 rpm, 37°C) over 30 days.



Figure 5. Weight (A), outer diameter (OD) (B), cross-sectional diameter (CSD) (C), Shore M hardness (D), compression resistance at 20-mm compressive strain (E) and percentage of elongation at break in tensile testing (F) for VR formulations before IVRT (D0), after 30-day IVRT in deionised water (D30) and after 21-day drying at 50 °C following IVRT (dried).

## Xinyu Zhao<sup>1</sup>, Peter Boyd<sup>1</sup>, Yahya Dallal Bashi<sup>1</sup>, Clare McCoy<sup>1</sup>, Xin Shen<sup>1</sup>, Dolores Lamb<sup>2</sup>, Narender Kumar<sup>3</sup>, Patrick Singer<sup>3</sup>, Lyann Mitchell<sup>2</sup>, R. Karl Malcolm<sup>1</sup>

<sup>1</sup> School of Pharmacy, Queen's University Belfast, Belfast BT9 7BL, UK; <sup>2</sup> Department of Urology, Center for Reproductive Genomics, Weill Cornell Medicine, Cornell University, New York, US; <sup>3</sup> Center for Biomedical Research, Population Council, New York, US.

## Results





